Mansour, The calculation of peak power during a jump from accelerometer data could be very sensitive to the inertial characteristics of the task. Mass will have to enter into the calculation somewhere and, in this case, the mass that the accelerometer is tracking will actually vary over time. This could potentially confound measurements of peak power, especially when comparing across different subjects. Average power over multiple jumps could be much more robust, such as described here: http://www.ncbi.nlm.nih.gov/pubmed/6681758 I agree with Dr Richards that you will probably want to use a filter that preserves the high-frequency content of the signal. If you have access to Matlab, there are some very powerful filtering tools that can be useful for your purposes. A recursive Butterworth filter is often used, but I have also had success using wavelet filtering, which can remove very tight bandwidths of noise without affecting the signal too much.

It is really good! Thanks a lot :)

Exactly .. just immerse your film in acetone and IPA then wash it with DI water and dry it with Nitrogen or Just use the spinner and ofcourse all of that should be done in clean room. if you will perform sonication make sure that your film "sample" is floating in the water bath to avoid the localized heat points in the base which will damage the nanorods. and make sure not to leave it over a min. as it is only for washing away the sticky particles and i'm not sure of the exact effect of long sonication time on ZnO nanorods.

Ok, I got the drift now. Thanks

You could also use tissue culture platic slides. Just cut some directly from culture dishes with a Dremel (I am serious...). Also, if you experience some cell detachment under flow (is it after 1 hour or 24h?), this is more likely due to your starvation condition or media. Could you precise your current protocol? Are you using HUVEC? Concernong the ECM composition on your slide, if you seed your cells for more than 24h prior your experiment, they will anyway produce a lot of fibronectin... explaining why, if you want to test the effect of different ECM proteins, you should seed your cells 4-5h prior your experiment

Gravitation is indistinguishable from a force-free state of rest, not inertial acceleration, no matter how local. Falling in a gravitational field, orbiting a planet, etc, are force-free experiences. It's only when gravitation is interrupted that inertial acceleration occurs. So the reason standing in a suspended elevator and being accelerated through space are indistinguishable if the reference frame is local enough is because both involve inertial acceleration. Inertial acceleration = inertial acceleration. What could be more trivial?

Dear Fatih: Good questions all. I take them up below: Management of Some Adverse Events from Prostate Cancer Androgen Deprivation Therapy (ADT) 1. PDE-5 Inhibitors for ADT-induced Sexual Dysfunctions Oral phosphodiesterase type 5 (PDE5) inhibitors are considered the standard of care especially in patients who received nerve-sparing RP and should be instituted as soon as possible to protect and prevent corporal endothelial and smooth muscle damage. But there are three cautions: (1) In RTOG 0215 Trial [Bruner et al., J Sex Med. 2011], the first randomized, double-blinded (cross-over) trial of a phosphodiesterase Type 5 (PDE-5) inhibitor in the treatment of ADT-induced erectile dysfunction, treatment-specific response occurred - and benefit was modest - in as few as 21% of patients, effectively leaving 4 out of 5 patients without relief. (2) Furthermore this landmark trial was short term: 24 weeks of which in only 12 was there active therapy. The more recent long-term randomized, double-blind, placebo-controlled Australian trial [Ilic et al., J Med Imaging Radiat Oncol. 2013] of the same agent (sildenafil) taken for 6 moths, with a 2-year follow-up, there was no difference in erectile function scores between the two groups (active and placebo) throughout the treatment period, concluding that although regular use of sildenafil may improve short-term sexual function, there was no evidence of long-term erectile function for patients while on medication. (3) we still lack any significant consensus on the exact timing, on the dosing, and on the optimal duration of PDE-5 inhibitors (and given their known equi-efficacy, application is across the entire class), nor its potential impact in other forms of prostate cancer treatment modalities including non-nerve-sparing RP. At this time, with no evidence of long-term benefit and equivocal data of efficacy in the short-term, with - at best - the vast majority of patients failing to achieve significant relief even at a modest level, we must conclude that prostate oncology is largely failing to provide clinically relevant remediation of many of the most QoL-compromising adverse events of ADT, whose total benefit-harm ratio is as yet to achieve a clearly favorable balance. Some Hope I will add a small but non-trivial ray of hope here in a procedure I have been advocating for some while both in this and in the general treatment context of erectile dysfunction, and although I use pharmaceutical-grade RYR (red yeast rice) standardized at no less than 10 mg monocolins component instead of the statin atorvastatin (Lipitor), the principle is the same and I have been able to match and exceed benefit obtained in trial data: the approach is to use a statin to improve response to a PDE-5 inhibitor (sildenafil) for remediating erectile dysfunction in patients initially irresponsive to PDE-5 inhibition [El-Sisi et al., Int J Impot Res. 2013]. Nonetheless, we need new solutions to capture still larger proportions of patients, some of which are slowly beginning to be researched. ADT-Induced Cognitive Compromise Data on cognitive decline, namely decline of memory and neurocognitive function, during ADT is to date inconsistent, although provisional evidence suggests the likelihood of a non-trivial problem especially as to spatial memory. One prospective Australian study utilized interval neurocognitive battery testing men (n=50) treated with ADT, finding that 48% demonstrated decline in one cognitive task, and 14% in two or more tasks at one year [Salminen et al., Br J Cancer2003.], but against this a different prospective trial (n=244) failed to demonstrate any evidence of neurocognitive function decline after ADT use for 12 months [Alibhai et al., J Clin Oncol 2010]. But the methodological quality of the aggregate literature on this issue I found to be of largely poor quality, beset by problems of low sample size and inadequate controls, and indeed there is no differentiation of intrinsic versus reactive cognitive decline, if any: it is not impossible I would suggest that some of the many adverse effects of androgen ablation therapy including vasomotor dysfunction, fatigue and anemia, and possibly other cardiometabolic side effects, may themselves contribute indirectly to the impairment of cognition. Thus need is the execution of a large-scale, methodologically robust randomized trial of prostate cancer patients randomized to ADT versus to watchful waiting, with planned analysis of metrics of cognitive decline and dysfunction. A trial close - but only close - to this, with some limitations, has just reported findings, the Polish ADT-QoL Trial [Wiechno et al., Psychooncology. 2013] where it was observed that there were no statistically significant differences between patients on ADT (n=88) and those without ADT (n=61) in cognitive function. This is still small, but the assignment to ADT and no-ADT is a requisite protocol; what is most lacking is standardized metrics, where here patient rated themselves. Finally, although to date no active intervention has shown significantly beneficial (data on estrogen is wholly inconsistent), nonetheless on a case observation level (n=180), I find improvement in any observed and reported cognitive compromise by virtue of aggressively addressing and remediating fatigue and anemia, adding consistent strength and aerobic training, and if necessary, supplementation with standardized ginsenosides (from Ginseng), standardized rosavins and salidrosides (from Rhodiola) and HD (high-dose) EGCG (a CAM intervention of some value in the "chemo-brain" of breast cancer therapies). For fatigue and chemo-brain in particular I have successfully used, across over a dozen malignancies LD-guarana (low-dose: negligible amounts of caffeine) based on the recent randomized, double-blinded, crossover clinical trial (Oliveira Campos et al., J Altern Complement Med. 2011) which demonstrated that guarana favorably remedied cancer-induced or chemotherapy-induced fatigue, with no significant increase in cardiovascular events, and no worsening sleep quality, nor any induction of anxiety or depression. Furthermore, these findings have been robustly confirmed in a meta-analysis of three clinical trials (Giglio et al. TANG, 2011) which found that guarana was an effective, inexpensive, and nontoxic alternative for the short-term treatment of fatigue (patients were breast cancer). Bone Interventions in Prostate Cancer Correct Fatih I would favor zoledronic acid (Zometa, Reclast) by a modest margin, although I can also countenance (besides Zometa) either alendronate (Fosamax) or risedronate (Actonel) but not ibandronate (Boniva) nor denosumab. Although denosumab and toremifene remain backup options, denosumab to date has shown a reduction in vertebral fractures but non-vertebral fractures, especially hip fractures, are the most critical ones, with higher mortality than many malignancies themselves (including breast and prostate cancer). Thus a bisphosphonate should be integrated within a program of optimal vitamin D (Alibhai and colleagues [Osteoporos Int. 2013] have recently shown benefit in remediating BMD and fracture risk induced from ADT), and a regular regimen of physical activity that includes both aerobic and strength/resistance training. Kind regards Constantine

Try to use acids like sulfuric acid ...hydrochloric acid ....in organic solvent

All the NEXAFS angle-resolved spectra contained in those works were computed by using ADF-External (copyrighted), an angle-dependent dft implementation made by Michele Romeo in Apr 2011. It works in parallel with the licensed version of the Amsterdam Density Functional code. Furthermoe, all the computations for covalent-clusters involved in these works were performed after a pre-processing step with Clustersat, to close properly the cluster geometry with hydrogen saturations to satisfy the covalent open bonds starting from an overflowing shell of atoms att he level of the periodic output of Quantum Espresso, which results in a very hard work when several hundreds of atoms in the same cluster have to be treated at once. This tool was developed by Michele Romeo in Feb 2012 for the specific aims of the Theoretical Research Group of the Chemistry Department near the University of Trieste.

I agree with Licun that increasing cell number can help plus the age of the mice, I faced similar problem with our mammary carcinoma model where we faced problems with tumor take rate sometimes and to solve the problem with less efforts we found doing transplantation in 3-4 weeks old mice is better than 6-8 weeks, may be you can try that as well.

I think that you could search a cytosolic production of these cytokines by a pre-treatment of cells with brefeldin A, fix, perm and marking by fluorescent antibodies, in order to establish the specific activation of cells using flow cytometry.

Try to use standard addition method and use LCMsMs system with Q_trap system

I think better you try to use the improve of BMI by that has low taste perception around the especific follow up.

Hi Jason. I agree with comment from Roberto Nussenzveig. But I was wonderng, have you checked youre PCR instrument? Do you have an assay you know will work "everytime"? It seems you have pretty good control on youre PCR generally, so I would have focused on the function on the PCR instument, is it working good? Does it have uniform temperature over the thermo block? Well nothing more to add, good luck and remember: Sometimes PCR = Polymerase crap reaction. Regards see

There is definitely quite a large body of evidence showing that humans are able to recognise objects they are only allowed to explore haptically when displayed only visually. So yes, at least for those two sensory systems, a cross-model transfer is present. However, I doubt that one may equalize these findings with the notion that the skin can "see" an object. I would rather suggest that an enormous amount of associative processing happens in between, mapping spatial, haptic information onto experience about to which kinds of visual objects such haptic sensations were linked in the past. However, I find it a fascinating question, as there is an ongoing discussion in psychology about whether synesthesia has to be regarded as a continuum everybody experiences to some degree. And in my opinion, synesthsia pretty well mirrors the experiences you described in your question.

Dear Friends, the TDS value is not very high. thus no RO requirement. Use roughing filters with in line coagulation system. the tretment plant would be; 1. In line Coagulation 2. Roughing Filter 3. Sedimentation (Optional) 4. Rapid sand filtration 5. Disinfection If detailed characteristics are given, i would be more specific.

I think researchgate is doing this job. Through this site we can share ideas and know each other.

I'm just curious, is "Normal termination of Gaussian" the only part of your output that's doubled? Are there any redundant parts in the results, for example "TOTAL ENERGY" line printed twice? It's possible that two nodes do the same job and they even generate a latency when they attempt to access the same output file, which in turn increases the duration of the job.

Protect your alcohol by willeamson synthesis to protect hydroxyl group by adding carbon atoms

Absolutely, and I believe it already is! Cross-cultural studies, sociology, and psychology (to name a few disciplines) have already been widely integrated into traditional kinesiology/physical education curriculums at the master's and doctoral levels. For example, how can we design programming sensitive to gender and cultural differences? The participation decline in adolescence, particularly for minority females, is troubling considering the associations between physical activity, healthy development, self-esteem, etc. Considering this decline, I know of exciting research (at least to me!) examining how to increase minority females' participation in physical activity through culturally sensitive programming.

Try dissolving it in 0.1% TFA in water more than 3 times and purify using reversed-phase HPLC

No problem! We usually test 5 different reference genes (GAPDH, SDHA, HMBS, HPRT1, TBP), but I guess the more, the merrier. :) But of course the selected reference genes will change depending on which samples and what experimental conditions we are testing. Cheers

Do you want to optimize a geometry of the system that consists of two distinct parts, just like a dimer of water? If that's the case, there's no problem with creating such thing with molden. Just draw the first molecule in Z-matrix editor and then connect the first atom of the second molecule to it, like it was its own atom. Then just change the proper distance in Z-matrix editor manually to reasonable value and continue to construct the molecule. You're operating on Z-matrix and not on cartesian coordinates, so you can easily change the relative location of the molecules just by changing three variables (the distance I spoke of plus one plane angle and one dihedral angle). Is it what you want to accomplish, or have I misunderstood you?